1980 - LC Labs becomes the primary worldwide source of PMA (phorbol 12-myristate 13-acetate; TPA), and this has continued uninterrupted for 37 years — more than 150,000 vials sold

1989 - LC Labs provides the first high-purity, low-cost Thapsigargin to the research market

1990 - first high-purity, low-cost Okadaic Acid

1991 - first high-purity, low-cost Calyculin A — and we remain the primary worldwide source for this widely-used phosphatase inhibitor

1995 - first isomerically pure, low-cost Go 6976

1996 - first high-purity, low-cost Bafilomycin A1

2002 - first high-purity, low-cost Rapamycin

2002 - first high-purity, low-cost FK-506

2003 - first high-purity, low-cost Leptomycin B

2004 - first high-purity, low-cost Staurosporine

2004 - first high-purity, low-cost Cyclopamine

2007 - LC Labs introduces the first group of high-purity, low-cost major Protein Kinase Inhibitors for prelinical oncology and related research